PB1805: INSIGHTS FROM ORAL AZACITIDINE EARLY ACCESS PROGRAM IN FRANCE: PATIENT POPULATION WITH ACUTE MYELOID LEUKEMIA RECEIVING ORAL‐AZA FOR MAINTENANCE OF COMPLETE REMISSION AFTER INDUCTION CHEMOTHERAPY.

Autor: Raffoux, E., De Botton, S., Ades, L., Carré, M., Cluzeau, T., Saillard, C., Heiblig, M., Beckerich, F., Gastaud, L., Dupuis, A., Richez, U., Dumas, P.‐Y.
Zdroj: HemaSphere; 2022 Supplement 3, Vol. 6, p1685-1686, 2p
Databáze: Complementary Index
Externí odkaz: